Arcus Biosciences (NYSE: RCUS) revenue
Arcus Biosciences reported revenue of $247.0m for fiscal 2025, 4.3% less than in fiscal 2024 ($258.0m). Since fiscal 2017 its revenue has grown by 17,380.5%, an average growth of 90.7% a year.
Arcus Biosciences's best year of the last 9 was fiscal 2021. The biggest drop was in fiscal 2022, −70.8%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $247.0m | −4.3% | −$386.0m | −156.3% |
| 2024 | $258.0m | +120.5% | −$330.0m | −127.9% |
| 2023 | $117.0m | +4.5% | −$340.0m | −290.6% |
| 2022 | $112.0m | −70.8% | −$280.0m | −250.0% |
| 2021 | $383.0m | +391.0% | $54.0m | 14.1% |
| 2020 | $78.0m | +420.0% | −$124.0m | −159.0% |
| 2019 | $15.0m | +79.6% | −$88.7m | −591.4% |
| 2018 | $8.4m | +491.2% | −$54.9m | −656.8% |
| 2017 | $1.4m | — | −$53.4m | −3,782.1% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Arcus Biosciences revenue compared with its sector
By revenue for its latest fiscal year, Arcus Biosciences ranks 234th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Arcus Biosciences, −4.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 232nd | Schrodinger | $255.9m | 23.3% |
| 233rd | LeMaitre Vascular | $249.6m | 13.5% |
| 234th | Arcus Biosciences | $247.0m | −4.3% |
| 235th | Keros Therapeutics | $244.1m | 6,775.0% |
| 236th | STAAR Surgical | $239.4m | −23.7% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Arcus Biosciences
- How much revenue did Arcus Biosciences make in fiscal 2025?
- Arcus Biosciences reported revenue of $247.0m for fiscal 2025, compared with $258.0m in fiscal 2024.
- How much has the revenue of Arcus Biosciences grown?
- Between fiscal 2017 and fiscal 2025 it went from $1.4m to $247.0m: 17,380.5% more, an average growth of 90.7% a year.
- What was the best year for revenue at Arcus Biosciences?
- Of its last 9 fiscal years, fiscal 2021, with $383.0m.
- Where does Arcus Biosciences rank in its sector by revenue?
- It ranks 234th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Arcus Biosciences come from?
- From the annual report (Form 10-K) that Arcus Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Arcus Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Arcus Biosciences: the Arcus Biosciences page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.